OpSens Announces Fourth Quarter And Fiscal Year 2021 Financial Results
23 November 2021OpSens Announces Fourth Quarter And Fiscal Year 2021 Financial Results Conference call on the results today at 11 a.m. ET Quebec City, Quebec, November 23, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today reported its results for the…
OpSens Successfully Completes 20-Patient In-Human Clinical Study for TAVR Procedure
23 November 2021OpSens Successfully Completes 20-Patient In-Human Clinical Study for TAVR Procedure TAVR market outlook for procedural growth remains highly attractive globally Quebec City, Quebec, November 23, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary technology, is pleased to announce the successful treatment…
OpSens to Host Fourth Quarter Fiscal Year 2021 Financial Results Conference Call and Year-End Update on Tuesday, November 23, 2021
17 November 2021OpSens to Host Fourth Quarter Fiscal Year 2021 Financial Results Conference Call and Year-End Update on Tuesday, November 23, 2021 Conference call to be conducted at 11:00 am ET Quebec City, Quebec, November 17, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based…
OpSens Will Participate at Stifel 2021 Virtual Healthcare Conference and Canaccord Genuity MedTech & Diagnostics Forum
10 November 2021OpSens Will Participate at Stifel 2021 Virtual Healthcare Conference and Canaccord Genuity MedTech & Diagnostics Forum Quebec City, Quebec, November 10, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company commercializing a second-generation fiber optic pressure guidewire to diagnose and treat coronary artery disease, announced today that Louis…
OpSens’ SavvyWire™ Featured at the Transcatheter Cardiovascular Therapeutics 2021 Annual Meeting in Orlando
8 November 2021OpSens’ SavvyWire™ Featured at the Transcatheter Cardiovascular Therapeutics 2021 Annual Meeting in Orlando Quebec City, Quebec, November 8, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device company currently commercializing its proprietary sensing technology in the interventional cardiology market, announced that its SavvyWire, developed specifically for transcatheter aortic valve replacement (“TAVR”),…
OpSens Successfully Treats First Patients in Human Clinical Study for TAVR Procedure
13 October 2021OpSens Successfully Treats First Patients in Human Clinical Study for TAVR Procedure Quebec, Quebec, October 13, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a cardiology medical device company providing innovative product solutions based on its patented optical technology, is pleased to announce the commencement of the human clinical study utilizing the SavvyWire,…
OpSens Presents at Lytham Partners Fall Conference
5 October 2021OpSens to Present at the Lytham Partners Fall 2021 Investor Conference – Tuesday, October 5, 2021, 9:30 AM
29 September 2021OPSENS TO PRESENT AT THE LYTHAM PARTNERS FALL 2021 INVESTOR CONFERENCE Presentation at 9:30 AM, Tuesday October 5, 2021 Quebec, Quebec, September 29, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a cardiology medical device company providing innovative product solutions based on its patented optical technology, announced today that it will present at…
OpSens Receives Approval from Health Canada to Initiate First In-Man Study For its New Guidewire For the TAVR Procedure
20 September 2021OPSENS RECEIVES APPROVAL FROM HEALTH CANADA TO INITIATE FIRST IN-MAN STUDY FOR ITS NEW GUIDEWIRE FOR THE TAVR PROCEDURE SAVVYWIRE, the first guidewire that aims to improve procedural efficiency and clinical outcomes for patients undergoing minimally invasive, Trans Aortic Valve Replacement (TAVR) Quebec, Quebec, September 20, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF)…
OpSens Appoints Lori Chmura to its Board of Directors
8 September 2021OpSens Appoints Lori Chmura to its Board of Directors Quebec City, Quebec, September 8, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, today announced the appointment of Lori Chmura to its board of Directors, effective September 8….